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Summary/abstract  
An array of local, national and global policy initiatives to control antimicrobial resistance (AMR) have 
been launched, but the effectiveness of these policies is not yet fully understood.  A stronger evidence 
base to inform effective policy interventions in high and low/middle income country (HIC and LMIC) 
settings, and across both the human and animal sectors, is needed.  We examine existing policies 
covering three domains:  1) responsible use, 2) surveillance and 3) infection prevention and control, 
and consider which policies are likely to be most effective at national and regional levels. Specific case 
studies highlight the complexities of applying AMR prevention and control policies across sectors and 
in widely varying political and regulatory environments, and demonstrate gaps that have emerged in 
the evidence base.  We make recommendations for policy action given the current state of evidence 
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and demonstrate that there is a need for more comprehensive AMR control policy evaluations 
including of their cost-effectiveness and generalisibility; by providing a contextual analysis of the 
political, regulatory and technical environments in which they are implemented. This is especially 
important across LMICs, and in the animal and environmental sectors. We conclude that standardised 
frameworks for evaluating AMR control policies should be developed and a cross-sectoral open-access 
central repository established to capture national and regional experience. A ‘One Health’ approach 
would enable an inclusive, sensitive and flexible process for AMR policy development that 
accommodates the needs and circumstances of each sector involved, and addresses specific country 
and regional concerns.   
 
Key messages panel 
 
 An array of local, national and global policy initiatives on antimicrobial resistance (AMR) 
have been launched worldwide. The effectiveness of these policies appears to be variable, 
with many gaps in knowledge.   
 
 Policies encouraging responsible use of antimicrobials in primary care/outpatient settings 
such as providing alternative prescribing options and back-up/delayed prescribing have 
been demonstrated to be effective. However, these and other interventions are context 
specific and not easily generalisable. Stewardship programmes in secondary care can be 
effective in encouraging responsible use of antibiotics and should be scaled up in both 
HICs and LMICs where feasible. Public awareness campaigns when sustained have shown 
some impact but should be implemented with caution particularly in LMICs, where the 
cost and impact of such campaigns needs better evaluation.  
 
 In the animal sector, curbing antibiotic use as growth promoter can be effective in 
reducing AMR. However, policy measures to achieve this must be coupled with adequate 
investment in improved infection prevention and control strategies for livestock, and 
effective mechanisms for remunerating veterinarians/prescribers and re-orienting their 
roles. 
 
 Reducing the demand and need for antimicrobials can be achieved through the 
implementation of effective Infection Prevention and Control interventions (IPCI) 
including vaccinations, hand washing, improved access to water and sanitation, and 
behaviour change. IPCI and surveillance in the animal and environmental sectors suffers 
from chronic underfunding and a significant investment of several billion dollars per 
annum is necessary to upgrade capacity in the vast majority of LMICs.  
 
 A global surveillance system should be created to enable improved between-country 
comparisons of AMR and antibiotic use through a programme of harmonising and 
integrating existing surveillance systems.  To do this requires the establishment of an 
adequately funded, cross-sectoral working group, with a mandate to negotiate with 
countries on a regional basis. For LMICs, additional focus is needed to improve monitoring 
of antimicrobial drug promotion and quality to curb the proliferation of counterfeits and 
substandard drugs. The sentinel surveillance of environmental settings likely to contribute 





 Increasing implementation of effective responsible use interventions and IPCIs globally 
should be linked to a simultaneous push for improved resistance surveillance and 
antimicrobial use monitoring data, thereby securing accountability. Countries reporting 
emerging drug resistance levels or high antimicrobial usage should be offered financial 
and technical support for implementing interventions  to help reverse such trends, but 
should also be incentivized to invest systematically domestically.   
 
 Knowledge gaps indicate that there is a need for comprehensive policy evaluations that 
include measures of cost-effectiveness, acceptability to populations and stakeholders; and 
assessment of the political, regulatory and technical environments in which they are 
implemented. Systematic reviews of existing policies are required across human, animal 
and environmental health as related to AMR control.  Standardised frameworks for policy 
evaluation should be applied and an open-access central repository established where 
national and regional AMR policy case studies can be captured.  
 
 A ‘One Health’ approach to AMR may help bridge gaps in the levels of commitment being 
shown to each sector and enable policy development that is inclusive, sensitive and 






 A range of policy initiatives have been launched to combat Antimicrobial Resistance (AMR). This paper 
explores the evidence base for policy interventions in a variety of contexts, from high and low/middle 
income countries (HICs and LMICs) and across the human and animal sectors. By applying a ‘One 
Health’ approach that bridges the interface between human, animal and environmental health, and 
accounts for factors such as the demands of food production and commerce1, we examine policy 
interventions across three broad AMR domains (Figure 1):  1) responsible use, through reducing public 
demand and supply by prescribers/ dispensers,  2) infection prevention and control to reduce the 
overall need for antimicrobials and 3) surveillance and monitoring systems,  which can function as 
mechanisms for assessing progress and making relevant stakeholders accountable for their part of the 
overall AMR control strategy. Specific country and regional case studies highlight the need for tailored 
solutions and the complexities of applying AMR control policies in widely varying political and 
regulatory environments. While the focus of this paper is largely antibiotic resistance, lessons can be 
learned from other areas of global health policy and are reflected in this analysis.  





Responsible use  
The term ‘responsible use’ implies that health-system activities and capabilities are aligned to ensure 
that patients receive the right medicines at the right time, use them appropriately, and benefit from 
them.2  
Policies encouraging responsible use, (i.e. curbing excess usage and reducing inappropriate demand), 
range from those focusing on healthcare workers in outpatient settings, stewardship programmes in 
inpatient settings, awareness raising national campaigns aimed at the public and structural reform 
policies designed to improve health systems at a national level.3,4 Unfortunately, while some success 
has been demonstrated in reducing resistance rates of indicator pathogens, policies have been 
context-specific and their evaluations have generally failed to adequately explore issues such as their 
applicability across both the public and private healthcare sectors or the governance and regulatory 
requirements (e.g. of over-the-counter sales) necessary to implement them effectively.  Table 1 
summarises several national examples demonstrating that responsible use policies in outpatient and 
primary care settings can reduce antimicrobial consumption, decrease resistance rates of specific 











Table 1: Selected examples of effective National Policies for Responsible Use in outpatient settings 
 
Example Action (best practice) Result Reference 
France National Plan to Control AMR 
 Surveillance for antimicrobial 
consumption 
 Surveillance for AMR 
 Infection control measures 
 Public Health Awareness 
 Education of Health Professionals 
 Rapid testing for Streptococcus 
pyogenes 
 Introduction of pneumococcal vaccine 
 
 Antibiotic consumption reduced by 23% 
(2002-2007) but stabilized thereafter. In the 
over 60 years age group though 
consumption subsequently increased 
reaching pre-intervention levels.  
 MRSA from blood culture reduced from 33% 
(2001) to 26% (2007) 
 Penicillin non-susceptible Streptococcus 
pneumoniae from respiratory, otitis media 
and other specimens decreased from 53% 
(2002) to 38% (2006). In nasopharangeal 
samples from children 3-40 months at day 
care centres in South Eastern France,  
penicillin non-susceptible S. pneumoniae 
decreased from 34% (1999) to 19% (2008) 
5, 6, 7 ,8 
 
 
Iceland Public media campaign on prudent use of 
antibiotics in children 
 Reduction in antimicrobial usage 
 Decrease in incidence of Penicillin non-
susceptible S. pneumoniae 
9 
Belgium Campaigns and activities by the Belgian 
Antibiotic Policy Coordination Committee 
(BAPCOC) 
 Public awareness to promote prudent 
use of antibiotics in the community 
 National Hand Hygiene Campaign 
 Establishment of antibiotic teams in all 
hospitals 
 Surveillance for antimicrobial 
consumption and resistance 
 Infection control measures 
 Introduction of pneumococcal vaccine 
 
Between 2000 and 2007  
 A 32% reduction in antibiotic usage  
 Macrolide resistance in S. pneumoniae 
decreased from 36.5% to 26%; and in S. 
Pyogenes (among patients presenting with 
pharyngitis) from 17% to 2% 
 Penicillin non-susceptible Streptococcus 
pneumoniae from invasive isolates 
decreased from 17.7% to 10.0%   
10 
Australia Antimicrobial restriction to reduce 
fluoroquinolone usage 
 Fluoroquinolone resistance amongst Gram 
negative bacilli reduced to under 5% 
6, 11, 12 
 
Thailand Antibiotics Smart Use (ASU) Programme:  
 Phase 1: Treatment guidelines and 
patient education 
 Phase 2:Expansion of network and 
integration of ASU into national 
policies 
 Phase 3: Sustainability through creation 
of social norms on rational use of 
antibiotics 
 Phase 1 successful in reducing antibiotic 
prescriptions.  
13 
South Korea Introduction of policy prohibiting physicians 
from dispensing drugs 
Antibiotic prescribing for patients with 
presumed viral illness decreased from 80.8% 
in 2000 to 72.8% in 2001  
14 
Taiwan  Policy prohibiting physicians from 
dispensing drugs 
 National Health Insurance stopped 
reimbursement for acute upper respiratory 
tract infections without proof of bacterial 
aetiology 
More than 50% reduction in antibiotic usage 




Pakistan Implementation of standardised approach 
to rationalise use of drugs in Acute 
Respiratory Infections at a Children’s 
Hospital in 1990 
Outpatient antibiotic usage decreased from 




Responsible use by healthcare workers 
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In outpatient primary care in LMIC settings, the ASU programme in Thailand13 demonstrated that 
alternative prescribing options were important factors in increasing physicians’ confidence to limit 
antibiotic prescription. The availability of appropriate alternative therapies such as oral rehydration 
and zinc for diarrhoeal diseases, and herbal medicines packaged in antibiotic-like capsules for viral 
upper respiratory tract infections helped achieve this. This may be an attractive policy option in many 
environments where private healthcare plays a large role in treating patients and prescriber 
remuneration is more heavily dependent on drug sales.  In HICs, a recent review describes a range of 
highly heterogeneous findings for responsible use interventions in primary care.18  For example, some 
educational programmes targeting prescribers have been demonstrably effective in research settings 
but have failed to show a decrease in antibiotic prescribing when applied at scale in real-world 
situations. Stewardship campaigns focusing on ambulatory and primary care prescribing behaviour 
have shown modest success on prescription rates.19-22 Most campaigns show around 10% reductions 
in prescriptions and appear effective only in the short-run.23,24  Multi-faceted campaigns that target 
both prescribers and consumers appear to yield better results than more narrowly designed 
interventions.25 Amongst the most promising policy options in primary care is “backup/ delayed 
prescribing” which describes interventions that create a delay for patients between prescription and 
the collection of antimicrobials for infections. These have been shown to be effective in reducing 
antibiotic use, without increasing morbidity or affecting patient outcomes.18,22,26, 27    
 
Hospital-based stewardship policies appear to have been better evaluated than those at community 
or national levels. The development and implementation of clinical antibiotic prescribing guidelines in 
secondary care provides the most compelling evidence of effectiveness with studies showing drops in 
prescribing of up to 80% for certain drug classes.18 A recent systematic review of interventions to 
support such implementation identified 89 studies across 19 countries and compared both persuasive 
and restrictive methods designed to improve hospital antibiotic prescribing practice. Persuasive 
methods advised physicians on how to best prescribe or gave them feedback. Restrictive methods 
limited how they prescribed (e.g. requiring approval from infection specialists in order to prescribe 
antibiotics). The studies showed that both methods changed prescribing habits and several also 
demonstrated a decreased number of hospital infections. The restrictive methods appeared to have 
a longer effect than persuasive methods up to 6 months post-intervention. However, the authors 
graded much of the evidence on effectiveness as ‘poor’ or ‘very poor’ and noted a paucity of robust 
cost-effectiveness analyses across the identified studies. Advocating these methods in resource-
constrained settings with limited regulatory capacity is problematic and not without the significant 
risk of compromising expenditure on other critical aspects of healthcare delivery. 28  
 
While there is some evidence of the effectiveness of responsible use policies aimed at curbing excess 
use in publicly funded healthcare systems, evidence from private sector is notably lacking.29 In areas 
of the world such as South Asia, where 80% of patients seek care in the private healthcare system, 
evaluating policies to regulate or modulate antimicrobial use is urgently needed. Case study 1 
illustrates the challenges that patients and their physicians routinely face when AMR control policies 
fail to adequately engage with the private healthcare sector. 
 
Responsible use and public awareness  
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There remains a considerable gap in the public’s knowledge of both appropriate antibiotic use and the 
causes of AMR, with levels of awareness and understanding varying significantly across countries.30 
Many patients believe antibiotics cure viral infections, do not understand the basic mechanisms of 
AMR30-32 and regularly self-medicate with left-over antibiotics.33, 34  
There has been a noticeable increase in information campaigns.3,35 aimed at improving knowledge on 
appropriate usage and at reducing antibiotic consumption by influencing demand.36,37,23 A campaign’s 
success also depends on social, cultural and geographical factors, as well as existing barriers to 
prescribing.38,39 Since 2008, European public AMR awareness-raising activities have largely centred 
around the introduction of a European Antibiotic Awareness Day (EAAD).40 Similar campaigns have 
also been conducted outside of Europe.41,42 Most campaigns aim to provide patient information 
(leaflets, posters), or through mass media communication such as billboards or adverts.23 Since the 
majority of antibiotics are prescribed in primary care, many campaigns focus on information about 
infections common in this context, such as respiratory tract infections. 43 
Campaigns such as the EAAD have received widespread and continued support from participating 
countries; however, their effect on AMR, antibiotic consumption and prescribing is difficult to 
evaluate.3, 34 Effects will be dispersed and may be very small, and few interventions have been 
examined in terms of cost-effectiveness.3, 23 It is not clear when awareness translates into lower rates 
of antibiotic prescriptions. Improvements in adherence to antibiotic treatment regimens are hard to 
measure, particularly for prescriptions in ambulatory care where intake is not supervised.44 Moreover, 
comparative assessments of the effectiveness of public awareness campaigns are problematic as 
different countries use varying parameters for evaluations and for measuring antibiotic use e.g. 
Defined Daily Doses (DDD) or number of packages prescribed per 1,000 inhabitants/day.45 An 
evaluation of EAAD effectiveness in the UK for instance concluded that the campaign had only led to 
a minimal increase in public awareness, with no observable reduction in antibiotic use.46 However, 
long-running campaigns, especially in Australia and France, have been associated with modest but 
consistent improvements in consumer awareness, as well as a reduction in antibiotic prescribing..47, 24 
What has proved to be particularly challenging is communicating the differences between bacterial 
and viral infections.30, 48  
  
Case study 1: The physican and patient perspective – how failure to engage the private sector in AMR control can 
impact health  
A 43-year old male patient with a past history of tuberculosis infection presented at a tertiary care centre in Karachi, 
Pakistan, with a one-month history of hemoptysis, fever and weight loss. Though microscopy of broncho-alveolar lavage 
(BAL) for acid-fast bacilli (AFB) and Line Probe Assay (Hain Genotype MTBDRplus) were both negative, the patientwas 
started on a treatment regimen on the basis of radiological abnormalities. The BAL culture was later identified as 
multidrug resistant M. tuberculosis (MDR-TB) including resistance to quinolones. No source for the patient’s MDR-TB 
could be identified. However, two years earlier he had been treated for a tuberculous pleural effusion. He had been 
compliant with his treatment but had procured medicines from the market privately.  
 
 
The patient was commenced on second line therapy with Kanamycin, Moxifloxacin, Ethionamide, Cycloserine and 
Pyrazinamide.. Whilst initial improvement was noted in his clinical condition over the ensuing three months, he 
subsequently began to deteriorate. A chest x-ray revealed increased infiltrates in the left upper lobe. Sputum culture 
and sensitivity testing showed the pathogen was now resistant to all first and second line agents; the patient had 
Extensively Drug Resistant Tuberculosis (XDR-TB) sensitive only to Linezolid.  Treatment was changed to a XDR-TB 
regimen including; Capreomycin, Linezolid, Moxifloxacin, Amoxicillin-clavulanate, Clarithromycin, Ethionamide, 
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Pyrazinamide, Cycloserine and PAS. The patient improved and his chest x-ray showed disease localization to the left 
upper lobe. M.tuberculosis culture and smear after six months’ of treatment were negative.   In view of emerging 
evidence supporting surgical resection as complementing chemotherapy for localized MDR-/XDR disease49, 50 the 
patient was referred for surgery. Unfortunately, surgery could not be performed due to limited operating room capacity 
for handling such infectious cases. The patient was continued on the XDR-TB regimen and at has remained smear and 
culture negative.  
Policy efforts to respond 
The private TB drug market in Pakistan, as in several high burden countries, is considerable – and mostly unregulated. 
Antimicrobials (including both first and second line anti TB agents) are easily available over the counter. Lack of controls 
and checks on the quality of medicines being sold results in the supply of substandard agents.51-53 A recent multi-
country study found that in neighbouring India, 10.1% of first-line Isoniazid and Rifampicin samples tested were 
substandard.54 
While a number of factors are likely to contribute to the reported increase in number of XDR-TB cases from Pakistan55 
poor quality of TB drugs and inappropriate prescription have a significant role in driving resistance. For example, both 
Pakistan and India have reported increasing quinolone resistance.56, 57 Frequent use of quinolones for suspected 
infections (including respiratory infections) significantly contributes to such increase.58 Despite quality-assured drugs 
being supplied to the public sector through initiatives such as the Green Light Committee (GLC) for MDR-TB at 
concessionary prices for second line drugs for MDR-TB treatment59 , the considerable private sector is simply not 
engaged with. 60, 61 The National Tuberculosis Control Programme of Pakistan has made significant strides towards 
disease control and is now expanding its engagement with the private healthcare sector. Drugs-for-performance 
agreements have been successfully applied in several public-private partnerships, as well as incentive based schemes to 
improve early case detection and encourage the reporting of suspected cases and improve surveillance coverage.29 
These efforts require further support and would be enhanced by legislation making tuberculosis a notifiable disease in 
Pakistan. The Chennai Declaration, a five-year plan to tackle antibiotic resistance in India62 may provide a blueprint for 
other countries in the region including Pakistan to adapt and adopt if demonstrated to be effective.  
 
  
Responsible use through structural reform and strengthened healthcare systems 
The challenges of poor governance and inadequately resourced health systems affect all aspects of 
healthcare delivery including the ability to implement effective AMR control policies at a national 
level.   Weak regulation and misaligned financing models for healthcare can create perverse 
economic incentives for providers. 
In Australia, the commendable success of reducing primary care use of fluoroquinolones, has been 
attributed to a policy of strong government regulation including a narrowed list of indications for 
quinolones through its national pharmaceutical subsidy scheme. Despite several years of preceding 
educational initiatives, no significant impact had been made on reducing usage but following 
introduction of the narrowed list and removal of the subsidy, quinolone usage dropped by 30% in 
the 1994-1995 period. Researchers, recognize that the policy to withdraw public subsidies was 
effective, in part, because of the high underlying price of quinolones in Australia – underlining the 
importance of understanding the national context of such policy successes.12  
In China, antibiotics are substantially overprescribed as drug sales revenue constitutes a major 
proportion of healthcare providers’ incomes.63 In response to increasing AMR, China’s first explicit 
attempt to rationalize antibiotic use came in the shape of national hospital guidelines (2004)64 and a 
concurrently launched containment policy, which sought to ban the sale of antibiotics to patients 
without prescription.65 The effectiveness of these policy measures was not systematically evaluated, 
and weak enforcement is likely to have limited their impact. 66 Further measures introduced in 
recent years include the establishment of a national taskforce to rationalise clinical use (2011), and 
new clinical regulations (2012) 67 for hospitals that define best practice and impose legal penalties 
for violations.68  Policy enforcement is key and the experience in China (case study 2) suggests that 
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strengthening the healthcare system is a pre-requisite: in this case, it involves the realignment of 
economic incentives by de-linking monetary compensation for prescribers from antibiotic sales.  
Strengthening national drug regulatory authorities may also have a role to play in monitoring the 
promotional activities of antimicrobial drug companies as well as ensuring their quality by limiting 
the proliferation of substandard and counterfeit antimicrobials. The pharmaceutical industry is 
known in some settings to pressurize both patients and doctors: patients through intense marketing 
campaigns76 and doctors through bribery.69 Well-publicised criminal investigations of irresponsible 
sales practices of GlaxoSmithKline in China and Poland, for example, demonstrate a policy shift 
towards the pharmaceutical industry more generally, by national authorities.70, 71 In recognition of 
the threat posed by counterfeits and substandard drugs in particular, the Indian government has 
adopted increasingly stringent sanctions on pharmaceutical producers and traders including possible 
life imprisonment.72   The impact of these more robust regulatory policies on marketing and sale of 
all drugs, including antimicrobials, remains to be assessed.  
 
Case study 2: Antibiotic Prescription in China: Systemic and Contextual Drivers 
In China, the prevalence of antibiotic use is very high. 63 In 2007, an estimated 90,000 tons of antibiotics were used in 
humans.73 The Ministry of Health (MoH) set up the National Healthcare Associated Infection Surveillance 
System (NHAISS) in 2001 to monitor antibiotic usage in hospitals,74 and the MoH National Antibacterial Resistance 
Investigation Net (Mohnarin) in 2004 to detect and monitor antibiotic resistance.75 Even though NHAISS’s data suggest 
that the prevalence of antimicrobial use in hospitals in China has decreased from 54.79% in 2001 to 46.64% in 2010,74 
Mohnarin’s data show that the prevalence of resistant bacteria (over 40%), particularly hospital-associated pathogens 
(over 60% for MRSA and ESBL (+) E. coli) remained high during the period between 2000 and 2011.75  
 
Perverse financial incentives that stem from the fee-for-service payment model adopted by state-owned healthcare 
providers are a primary driver for overprescribing of drugs.76 As such, the national rural social insurance scheme has 
inadvertently led to the overprescribing of antibiotics in those who are covered, by lowering financial barriers to 
accessing healthcare.77 Subsequent trial modifications within the scheme have demonstrated that changing the 
payment model from fee-for-service to a capitated budget with pay-for-performance was effective in reducing 
inappropriate and overprescribing of antibiotics.78 
 
Without altering the overall financing model of healthcare, overprescribing is likely to persist. Financing of state-owned 
healthcare providers in China relies very heavily on the revenue of pharmaceutical sales (a government-granted 15% 
mark-up is applied to the procurement price of a pharmaceutical product);79 as a result, a doctor’s salary is typically 
linked with the volume and financial value of the drugs and services they provide. Recognising the need to delink 
doctors’ salaries and hospital incomes from prescribing practices, the MoH launched the National Essential Medicines 
Policy (NEMP) in 2009 (its full implementation is limited to primary care). A key element of the NEMP is a zero mark-up 
policy whereby essential medicines are sold at procurement price plus a fixed distribution cost, leaving no profit margin 
for healthcare providers.80 Instead, financial subsidy is provided by government to healthcare providers to encourage 
greater and more rational use of essential medicines.81 Apart from eliminating financial incentives, the NEMP aims to 
rationalise prescription from other angles, including improving drug quality and accessibility to patients, and responding 
to regional requirements for specific drugs. However, currently available studies find mixed evidence for the impact of 
NEMP on antibiotic prescription in primary care: despite some potential improvements, overuse and irrational use of 




Responsible use in the animal sector 
AMR in animals represents a significant problem for human health86-88 and the emergence of 
multidrug resistant bacterial strains and strains resistant to antimicrobials considered critically 
important in human medicine is of concern.89-91 Bacteria hosted by animals can reach humans through 
direct contact, food and/or the environment.92 Non-therapeutic use of antimicrobials in animals for 
growth promotion has been associated with high levels of AMR in the animal reservoir. This situation 
11 
 
has occurred in many countries and is well-documented. 84,93,94 In many countries different 
stakeholders argued against banning antimicrobial grown promoter (AGP) use, often referring to a 
suggested negative economic and animal health effect. 95  However, other economic incentives still 
continue to affect the over-use of antimicrobials in most countries. To remove the economic 
incentives for antimicrobial overuse by veterinarians, some governments have legislated to reduce 
veterinarian profit from direct antimicrobial sales. In Denmark (1994), such interventions resulted in 
a 40% reduction in total use of antimicrobials, and a reduction in tetracycline use from 37 to 9 tons 
between 1994-5.96 To compensate veterinarians for income loss from reduced antimicrobial sales, 
new advisory roles were created, e.g. providing technical support to farmers on improving animal 
health and biosecurity without antimicrobials.  For big livestock holdings, monthly veterinary 
consultations were made mandatory. These actions seem to have resulted in more efficient and cost-
effective management systems (case study 3).  
Dutch initiatives have also resulted in reductions in animal antimicrobial use (56% between 2007 and 
2012). Critical to the Dutch plan were: a Memorandum of Understanding between the animal sectors 
and the Dutch Association for Veterinarians (2008); a mandatory antimicrobial reduction regime 
implemented by government demanding a reduction of 70% by 2015 (compared to 2009 levels); 
introduction of farm health and treatment plans with specified antibiotics; and prohibition of use of 
new antibiotics.97  
 
In many LMICs, the post-colonial era has brought changes in livestock/meat production industries, 
with significant shifts in land holdings and usage. A mix of large producers and smallholders often 
operate in parallel, with poorer communities moving from subsistence to cash-based economies. Loss 
of economies of scale have resulted in big drug suppliers moving to fewer regional centres, with ad 
hoc traders filling the vacuum; at the same time increasing numbers of cheap generic drugs have 
become available.98 While improving smallholders’ access to drugs, these factors have compromised 
the quality and range of products available in environments with weak regulation, licensing delays, 
cash flow problems and distribution difficulties.  Surveys on antimicrobial usage in the animal sector 
in LMICs are patchy but indicate a proliferation of abuse and a high level of farmer-prescription, with 
around a third of countries allowing antibiotics over the counter.99, 100  Furthermore, many livestock 
owners engage unskilled people to treat animals, resulting in sub-optimal dosing, incorrect 
administration, arbitrary drug combinations and non-observance of withdrawal periods.101-104 Novel 
stewardship interventions began in the 1990s, with experiments in community-based animal health 
workers encouraging local control of drug use. However, these efforts were often undermined by 
inadequate supporting legislation and poorly paid veterinary officers supplementing salaries with drug 
sales.105, 106   
Case study 3: Limiting antibiotic use in the animal sector- the policy evidence from Denmark 
AGPs for animals were introduced and promoted by the drug industry, and generally accepted in animal husbandry for many 
years. Although some scientists at an early stage postulated that AGP use could lead to antimicrobial resistance in 
microorganisms which could then spread to humans,107 the issue has remained contentious, with limited evidence available 
to quantify the increased risk of AMR spreading to humans from use in animals. One of the main reasons for this uncertainty 
is the complexity of evaluating the relative importance of different transmission routes from animals to humans, especially 




Although many LMIC veterinary authorities have adopted international standards and regulations on 
drug use designed to facilitate control of AMR, the capacity to implement these guidelines is lacking.113 
Some NGOs have provided a middle ground in capacity building, education and facilitation of 
improved stewardship in LMICs and report improvements in both veterinary and para-veterinary 
sectors.105,106,113,114 The majority of these programmes are limited in scope, however, and have not 
been robustly evaluated. 
Raising awareness in the animal sector 
In the animal sector there is limited evidence of the effectiveness of awareness-raising policy 
initiatives changing prescribing behaviour by veterinarians or varying antimicrobial use by livestock 
farmers in the absence of strong central regulation. In America, where lobby groups can exert 
significant influence over law and policymakers, an increasingly coordinated awareness raising drive 
both amongst the public and healthcare associations contributed to the introduction of the 
Preservation of Antibiotics for Medical Treatment Act (2013) bill to Congress. 115 The bill which would 
mandate introducing regulations to curb antibiotic use in animals, appears to have stalled in the 
Senate with fierce opposition from industry groups.116, 117 Consequently, there is despondency over 
the bill’s potential to strengthen the regulatory framework needed to curb excess use, with some 
analysts estimating a minimal likelihood of it being enacted.118In the latest salvo in this ongoing 
debate, a new bill has been introduced that would require the Federal Drug Administration to 
withdraw product approval for antimicrobial use in animals, if a drug maker cannot demonstrate that 
its antibiotic poses no risk to human health.119 The growing public awareness around the debate 
appears to have influenced food retailer and consumer demand too, with McDonald’s recently 
announcing it will phase out the use of chicken raised with antibiotics important to human health – 
thus pressurising competitors to follow suit.120 
Despite accumulating evidence showing that AMR bacteria from farms resulted in human health problems, the level to which 
this was due to AGP and agricultural antimicrobial use in general remained debatable.108 As early as 1969, the Swann 
Commission in the U.K. recommended that antimicrobials should not be used as AGP when they were used as therapeutic 
agents in human or animal medicine, or when associated with the development of cross-resistance to antimicrobials used in 
people.107 This led to a ban of all use of AGP in food-animals if these antimicrobials were also important for therapeutic use 
in humans - first in the UK, and subsequently in the EU. The action was enforced on individual antimicrobials, but did not 
consider the chemical analogues of these drugs. Therefore, the use of antimicrobial analogues as AGP in Europe essentially 
allowed for the continued selection of cross-resistance to human therapeutic drugs.   
It was several decades after the publication of the Swann Report before serious concerns around AGPs arose again. In Sweden, 
AGP use was banned in 1985, however, no scientific documentation, including baseline studies related to this ban have been 
published. In Denmark, concern was heightened by new findings regarding Avoparcin use as an AGP. Avoparcin is a chemical 
analogue to Vancomycin, an important human antimicrobial. A survey in 1995 revealed the first evidence that Avoparcin leads 
to the emergence of AMR; researchers found Vancomycin-resistant Enterococcus bacteria (VRE) in 80% of the chickens from 
conventional (Avoparcin using) farms, whereas none were found in chickens from organic farms.109,110 In humans, a similar 
increase in VRE bacteria was seen, which could either be due to Vancomycin use in humans, or to human consumption of 
contaminated meat.110, 111 Based on the relatively limited data presented, Danish farmer organizations agreed to a voluntary 
withdrawal of Avoparcin use in chickens (leading to a drop in VRE in chickens to <5% by 1998). In addition, the new Ministry 
of Food, Agriculture and Fisheries became responsible for managing the farm-to-fork chain, alongside the Ministry of Health, 
and initiated the integrated surveillance program, DANMAP. Based on the data from this surveillance program, further 
decisions were taken to reduce and eventually ban the use of AGP in Danish agriculture in 1998.  In 2003, the EU decided to 
phase out all use of AGPs by 2006.112 Neither the Danish nor the EU bans seem to have affected agricultural productivity 
negatively and Danish data for national pork production, documents a significant increase in the number of pigs produced 
from 1998 to 2011 (23 to 30 million pigs annually).95 
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In LMICs, a lack of awareness amongst farmers is high, with one study conducted in Tanzania showing 
that while most livestock keepers were using antibiotics to treat their animals with some observing a 
withdrawal period prior to slaughter, approximately 40% were not aware of any related possible 
human health threats.121 Well-evaluated policy initiatives aimed at raising awareness in the animal 
sector are conspicuous by their absence, reinforcing a continuing theme of poor evidence from LMICs.  
 
 
Infection prevention and control  
In human healthcare settings 
Infection prevention and control interventions (IPCI) can minimize the spread of pathogens, including 
those that are resistant, decrease the likelihood of infection in healthcare settings and reduce the 
overall need for antimicrobial use.122,123 Controlled clinical studies as well as international 
benchmarking of infection control practices and AMR infection rates have provided valuable 
information for advocacy and established a minimum set of evidence-based practices for control of 
epidemic or endemic AMR pathogens in different healthcare settings.124 In particular, it is now 
established that hand hygiene is the most effective measure to prevent transmission of resistant 
bacteria during healthcare delivery, as shown in the successful control of MRSA through national 
campaigns to improve hand hygiene compliance.125,126 The implementation of WHO’s hand-hygiene 
strategy is feasible and sustainable across a range of settings in different countries and leads to 
significant compliance improvement.127   
 
To be sustainable, IPCIs must target routine care practices, environmental reservoirs and be adapted 
to local priorities.128 Accordingly, the WHO proposed a core concept of IPCI elements (hand hygiene, 
environmental cleaning, disinfection and sterilization, education of staff) for healthcare facilities, and 
encourages national authorities to ensure application. Implementation remains challenging in LMICs, 
with frequent lack of access to even basic IPCI mechanisms resulting in a weak evidence base to 
support their introduction into LMIC healthcare settings.129-131  
 
IPCI in the community 
Reducing the burden of infections (both incidence and transmission) and subsequent need for 
antibiotics must therefore be a prime focus, by promoting hand hygiene with soap, improving access 
to clean water and sanitation, vaccines (e.g. pneumococcal, cholera, typhoid fever) and more disease-
specific measures such as reducing sexually transmitted infections through condom use.132-135 
Conversely, other interventions may exacerbate resistance, such as the large-scale use of azithromycin 
for yaws eradication potentially affecting resistance in other treponemes.136 Several studies have 
shown significant reduction in resistant S. pneumoniae following the introduction of multivalent 
pneumococcal conjugate childhood vaccines, both in the vaccinated and the general population 
(through herd immunity).137-139 The integration of vaccination programmes into broader AMR control 
strategies remains an under-evaluated policy intervention, with global initiatives operating mostly 
separately. Encouragingly, financing for evidence-based IPCI has increased and collaborations are now 
operational worldwide through local, national, regional and international networks (see table 3).  
 
Table 3: Selected examples of successful global infection prevention initiatives  
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Infection prevention initiative Reference 
The ‘Clean Care Is Safer Care’ campaign by WHO focuses on hand hygiene 
compliance among health care workers. Since its inception in 2005, 134 WHO 
Member States and autonomous areas have participated in this initiative, reaching 
9 million healthcare workers and more than 17 000 health-care facilities have 
committed to improve hand hygiene. 
140 
The GAVI Alliance finances vaccines and, to some extent, immunization services in 
developing countries, those with a gross national income per capita (according to 
the World Bank) below or equal to USD 1,570 (as of 2014). GAVI’s vaccine portfolio 
includes several vaccines for illnesses that would otherwise be treated with 
antibiotics (pneumococci, Haemophilus influenzae and rotavirus (since diarrhoea 
is often inappropriately treated with antibiotics rather than oral rehydration salts 
and zinc).  
141 
The Global Fund Against AIDS, Tuberculosis and Malaria has financed the purchase 
of more than 310 million long-lasting insecticidal mosquito nets, to combat malaria 
and indirectly reduce the risk of emergence and spread of resistant malaria. 
142 
The World Bank through its Water Partnership Program has allocated USD 24 
million to improve the quality of drinking water and sanitation services in low-
income countries with additional funding being allocated through the next phase 
of the program. 
143 
UNFPA procures and distributes condoms (both male and female types) in 
developing countries as well as actively promotes other practices (e.g. male 
circumcision) to limit sexually transmitted diseases of bacterial origin, particularly 




IPCI in animals 
Effective IPCIs in the animal sector provide some notable examples. Policies encouraging the adoption 
of ‘All-in-All-Out’ farming systems (i.e. production systems whereby animals are moved into and out 
of facilities in distinct groups, preventing co-mingling and with facilities normally being cleaned 
between animal groupings) and reformulation of animal diets have been effective in reducing 
antibiotic consumption while maintaining livestock growth rates.145-147  
Successes in LMIC settings include the widespread adoption of the infection-treatment immunization 
method for East Coast Fever control in East African cattle. The technique, based on injecting cattle 
with partially attenuated sporozoites of Theileria parva concurrently with long-acting oxytetracycline, 
has proved effective over several decades in preventing infections, with no known contribution to the 
AMR burden.148 
In aquaculture too, the remarkable success demonstrated by countries such as Norway in reducing 
antibiotic use through vaccination programmes are well-described. However, developing policies to 
progress these limited national successes to other countries has been slow.149 The tripartite 
agreement between WHO-OIE-FAO (World Organization for Animal Health and UN’s Food and 
Agriculture Organization, respectively) has piloted several One Health projects to do this150 Despite 
some successes, it is clear that there is chronic under-investment in IPCIs in the animal sector. The 
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World Bank estimates the funding needed for 60 low-income and 79 middle-income countries to bring 
their animal infection prevention and control systems up to OIE/WHO standards ranges from US$1.9 
billion to US$3.4 billion per annum.151 Funding agencies have thus recently begun to apportion more 
spending to ‘One Health’ initiatives, but the global effects of this policy shift in funding AMR control 
specifically remains to be evaluated.152, 153  
Surveillance   
Surveillance of antibiotic use and resistance in humans 
Surveillance of antibiotic use and resistance is a cornerstone of efforts to control AMR.154 The 2001 
WHO Global Strategy88 embedded surveillance of resistance, monitoring of antimicrobial usage and 
disease burden as key components. Between-country comparisons can be a major political driver for 
change and increased focus as shown in the European experience with the EARSS and ESAC networks 
thereby functioning also as accountability measures for countries.155, 156 The success of the two 
systems has seen the WHO Regional Office for Europe expand use of the ESAC-Net method to cover 
14 additional countries in Europe.157 Moreover, several countries within Europe (e.g. France, Scotland, 
UK) and outside Europe (e.g. South Korea, Turkey) have now successfully implemented governmental 
targets based on public reporting of surveillance data. 158 ,159  
Despite their obvious importance, most international surveillance systems outside of Europe have not 
been formally evaluated in terms of validity, sustainability and long-term impact on antibiotic 
resistance. The evidence base to determine the most cost-effective systems for surveillance of 
antibiotic use and resistance remain weak worldwide.  Policymakers in all settings need help deciding 
on the most efficient surveillance systems to maximise limited resources; should countries invest in 
systems of continuous ongoing surveillance of all healthcare settings or can sufficient data be gathered 
with more limited sentinel surveillance or periodic prevalence studies? 160 
For monitoring antibiotic use, there is debate about the best indicators in different settings, and the 
value of aggregate-level versus individual patient-level information for guiding stewardship strategies; 
aggregated consumption data do not allow evaluation of the quality and adequacy of individual 
prescribing decisions, although they provide measurable estimates of trends for benchmarking.161  
Several experts and policy makers suggest point-prevalence surveys of antibiotic use as a simple 
method to solve these issues.162  
Unsurprisingly, there are significant differences between surveillance system needs due to varying 
cultures, seasonal practices and population dynamics (case study 4).  In LMICs with weak health 
systems and competing public health problems, constraints of infrastructure, trained personnel, data 
collection and coordination result in diverging approaches and indicators to monitoring antibiotic use 
and resistance.163,164  
Case study 4:  New regions of collaboration; Developing a policy framework for AMR control in a region of exceptional 
Human, Animal and Microbiome mix and flux 
The Gulf Cooperation Council (GCC) is a regional grouping of six high-income Arab states; Saudi Arabia, Oman, UAE, Kuwait, 
Qatar, and Bahrain.   As populations have grown, so too have health budget allocations, and vast sums are expended on 
public and private sector health facilities. However, health and information systems directly affecting surveillance are 
lagging behind. A recent WHO report has indicated that, despite legislation, monitoring and evaluation of data remains 
weak; the EMRO region’s AMR surveillance systems, including WHONET, and the GFN (Global Foodborne infections 
Network), have functioned poorly since they began in 2005.165 ,166    
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The absence of a global AMR surveillance system to provide reliable and validated AMR data from all 
continents results in significant knowledge gaps. Although several regional /national surveillance 
networks have been successfully established during the last two decades, most relate to HICs or 
specific pathogens (e.g. Global Foodborne Infections Network for foodborne pathogens, Salmonella 
spp and Campylobacter spp; WHO’s Gonococcal Antimicrobial Surveillance Programme). Most AMR 
networks do not have sufficient resources to standardise and quality-assure diagnostic methods for 
detection of resistance, and data are often not systematically collected or geographically 
representative.  Hence, they have limited effectiveness as early/rapid warning systems or in 
monitoring emerging AMR trends.  To facilitate timely coordinated containment action at the global 
level, the WHO’s International Health Regulations could provide the legal framework for early 
detection and outbreak control of emerging pan-resistant bacteria.174  
 
SURVEILLANCE CHALLENGES     
 
Published reviews have highlighted the growing threat posed by AMR in the GCC; frequently linked to lax regulation and 
inappropriate usage of antimicrobials.167, 168 To better understand the extent of the threat, surveillance is essential. 
However, there are several challenges to improving surveillance in the region.  First, a lack of standardised data collection 
on health indicators is compounded by the presence of over 21 million foreign migrant workers, who constitute 45% of the 
resident GCC population but mostly remain outside the health indicator data for the region. Second, the region has 
significant transitory population flux (tourists, transit passengers and migrant workers) with its associated microbiome.  
Also, unique to the region is the annual Hajj gathering in Saudi Arabia, of up to 3 million pilgrims from every country of the 
world, over a 3-4 week period.169 The size and variety  of the microbial biomass that gets transported, mixed and re-
distributed on such a massive scale is beyond the capacity of any available system to assay and track the AMR organisms. 
Mass movement of microbes in the GCC is also linked to the industrialization of food production. Together the GCC 
countries import $25.8 billion worth of the estimated total estimated $1 trillion global Halal meat market annually.  While 
the microbial carriage rate in imported livestock or frozen poultry and meat remains undocumented, reports on fresh 
chicken and meat in local markets show a significant rate of microbial contamination with multi-drug resistant bacterial 
isolates.170 ,171 
 
There is also a significant live animal trade in the region. Livestock are imported to feed growing populations and for 
sacrificial purposes at events such as the Hajj. The GCC accounts for 70% of Australia’s live sheep exports. While the 
application of laws generally remains weak, enforcement is gradually improving with the GCC livestock quarantine Law no 
8 (2003) first applied notably in 2012 to prevent a shipload of sick and dead Australian sheep arriving at any GCC ports. An 
example of an effective policy designed to maintain import standards while not adversely impacting exporting countries, 
is the public-private partnership of Saudi investors with Somalia.  The partnership established quarantine facilities in 
Somalia, a major exporter of livestock to the region. Consequently, Somalia’s ports now operate under international 
standards and enable disease-free exports of animals to a wider market, while adding value to the trade by providing 
ancillary services and increased employment in Somalia.172 New regulatory measures in this sector are now emerging that 
will improve disease detection in animal and food products; Dubai has set up the International Center for Halal Food and 
Product accreditation.  Surveillance testing of drug-resistant microbial contamination could easily be incorporated within 
these existing regulatory measures.  
 
To tackle AMR more broadly, a series of collaborative solutions were proposed following the 2013 World Innovation 
Summit for Health (WISH), supported by the Qatar Foundation, including strengthening the role of the GCC Center for 
Infection Control in the development and implementation of policy and procedures for regional AMR control and 
prevention.173 These efforts are expanding and gathering pace in more GCC settings through the WISH forum. A pan-GCC 
approach to AMR  surveillance is  thus feasible; to date, regional collaboration on health regulations has encouraged GCC 
countries to adopt several unified policies, including a ‘group purchasing tenders’ system to meet their pharmaceutical 
needs. Designed primarily to reduce costs, the system can also be used to ensure quality standards for antimicrobials, 
monitor usage and demonstrates that successful between-country collaboration is possible.    
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It has been suggested that laboratory and epidemiological surveillance should become part of a simple 
road-map where an agreed minimum dataset could be shared internationally.175 This goal is 
challenging. Many healthcare facilities (particularly in the private sector) are reluctant to share AMR 
data, wary of reputational damage. Similarly, at a national level, widespread information about AMR 
is thought to negatively impact on exports and medical tourism.176 This indicates that contributing 
data to both national and international surveillance may need to be mandated to be effective. 
Additionally, in LMICs there is a paucity of laboratories with the capacity to perform quality-assured 
microbiology and drug sensitivity testing.177-180 Vertical programs have been able to generate 
resources to overcome some of these obstacles and to provide infrastructural support for drug 
resistance surveys in a number of countries, but these are restricted to a few diseases.181-183 Wider 
efforts to improve quality are linked to quality assurance and accreditation programs and some 
notable successes have been achieved in Africa.182-184  
Table 2 summarizes important international, publicly-funded, voluntary surveillance systems of AMR 
pathogens, highlighting specific strengths and weaknesses.  Notable is the widely distributed WHONET 
software for local laboratory support and standardized AMR reporting. Despite its 25-year history, this 
tool has not been fully exploited nor upgraded for collaborative, international surveillance of AMR, 
despite early promises and a few significant exceptions.185, 186   (361) 
Table 2: Strengths and weaknesses of large-scale, international public AMR reporting and surveillance 
systems of AMR in humans 
Name / Organisation Coverage Strengths Weaknesses 
WHONET (WHO) Worldwide (110 
countries) 
Standardized laboratory 
software support and AMR 
reporting tool, helping to 
monitor and manage AMR locally 
and regionally 
Underused for global AMR 
surveillance and policy making 
Lacking commitment to upgrade 
software tool to gather AMR data  
EARS-net (E-CDC) Europe (29 countries) Surveillance of invasive 




Not real-time, not used as early 
warning system of emerging and 
novel AMR trends and pathogens 
Geographic variation in validity 
and representativeness of data 
CAESAR (WHO/Europe) Eastern Europe and 
Central Asia (13 non-
EARS-net countries of 
the WHO European 
Region) 
Setup of national AMR 
surveillance compatible to EARS-
Net so that an overview can be 
obtained for the entire European 
region 
Many non-EU countries lack 
routine surveillance capacities on 
which AMR surveillance has to be 
built 
ReLAVRA (PAHO) Americas (21 countries) Analyses susceptibility data from 
all isolates at country level and 
collates the data from 
participating countries. 
Provides support for  
local interventions to contain 
AMR 
Ensures continuous quality 
improvement 
Lack of resources and local 
commitment in some countries. 




Surveillance and Response 
(CDC) 
Africa (43 countries) Strengthens the capacity of 
African countries to conduct 
effective surveillance activities 
Uses data thresholds to trigger 
epidemiological investigations 
Includes few pathogens only, not 
focused on AMR  
Global Emerging Infections 
Surveillance and Response 
System (GEIS)  
Worldwide (>30 
countries)  
Develops, implements, supports 
and evaluates an integrated 
open access system for timely, 
actionable and comprehensive 
health surveillance information 
for antimicrobial resistance, 
gastrointestinal infections, 
febrile and vector-borne 
infections, respiratory infections 
and sexually transmitted 
infections 
Coverage limited to host nations 
supported by the US military 
Worldwide Antimalarial 
Resistance Network (WWARN) 
Worldwide Provides high-quality data 
resources, customised research 
tools and services, and a global 
platform for exchanging scientific 
and public health information on 
malaria drug resistance 
African regional networks to 
monitor emerging resistance failed 
to attract sustainable funding. 
Gonorrhoea Antimicrobial 
Surveillance Programme 
(GASP) in the Western Pacific, 
South-East Asia, Europe, South 
America and the Caribbean 
Worldwide Advocates and collate data on 
gonococcal resistance in 
different regions of the world  
Lacks financial and political 
commitment from countries, WHO 
and donors.  No real time, 
geographically representative data 
to inform treatment strategies in 
all regions. 
The Global Antibiotic 
Resistance Partnership (GARP) 
India   
Kenya  
South Africa   
Vietnam  




Network of institutes working on 
antibiotic resistance in low-
income and middle-income 
countries. 
Data manly collected from large 
academic centres.  
Alliance for the Prudent Use of 
Antibiotics (APUA) 
 
66 countries in Africa, 
Asia, and Latin America 
Conducts large-scale national 
and international research and 
educational projects to control 
and monitor antibiotic resistance 




Surveillance in animals and the environment 
To optimize the use of surveillance data for public health action, comparative data are needed from 
national, regional and global levels.187 The OIE has determined that 111 (73%) of 178 member 
countries have no official system for collecting data on antimicrobial use in animals. In Africa and the 
Americas this percentage rises to 95% and 96% of countries respectively. Significantly, in policy terms, 
35% of these countries still have no official plans to establish national surveillance and monitoring 
systems on antimicrobial use in animals.188  
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One of the first national integrated animal (and human) surveillance programs was initiated in 
Denmark in 1996 (the Danish Integrated Antimicrobial Resistance Monitoring and Research Program, 
DANMAP) as a collaboration between commercial and public stakeholders, and human, food and 
animal health sectors working in the farm-to-fork food chain.189 Through DANMAP, the VetStat 
database was initiated to monitor antimicrobial use at the single farm level and was instrumental in 
creating the Danish ‘Yellow Card’ system – a national  antimicrobial monitoring and reduction tool 
introduced in 2010. Individual farmers and veterinarians with exceptionally high antimicrobial use now 
receive a yellow card, followed by a series of injunctions if usage is not reduced within given time 
limits. The initiative has resulted in year-to-year reductions in total antimicrobial use in animals of up 
to 20%.190 In the EU, several other countries collect similar datasets, thus enabling between-country 
comparisons of antimicrobial use.191  The European Medicines Agency (EMA) in 2009 launched ESVAC 
(European Surveillance of Veterinary Antimicrobial Consumption), which now monitors animal use of 
antimicrobials in 25 countries through sales data.192  
In LMICs there are a few, mostly cross-sectional studies on antimicrobial resistance in isolates from 
animals or animal products in the food chain. For example, Salmonella resistance was detected in over 
79% of isolates from an abattoir study in Kenya, but studies done on AMR in human patients did not 
confirm a link.193 Almost no longitudinal studies or surveillance systems are functioning, few countries 
have adopted WHONET194  and the OIE Standard and Codex Alimentarius Guidelines are not yet 
applied. The need for improved surveillance in animals is clear, but policy initiatives to achieve this 
have made little progress beyond emphasising the scale of the problem.180, 195 
 
In recent years, studies have highlighted the presence of AMR in environmental bacterial samples. 
These suggest a risk of AMR spreading from hospital and pharmaceutical effluent, as well as from 
sewage systems and water treatment plants. Slurry from livestock farms has also been implicated.196, 
197 Developing sentinel AMR surveillance and sampling systems for higher risk environmental settings 
would thus seem an appropriate strategy for HICs and should be considered where technically feasible 
and affordable in LMICs. However, no countries have established such systems systematically outside 
research settings.  
 
Insufficient evidence base 
Our analysis demonstrates that lack of progress on combatting AMR is partly due to an insufficient or 
poor evidence base for the effectiveness of the myriad policies already existing across the human and 
animal sectors in both HICs and LMICs. Even where policies have demonstrated benefits in reducing 
antimicrobial use or impacting resistance, robust policy evaluations have been lacking, with little 
available information on cost-effectiveness, and inadequate descriptions of the technical, political and 
regulatory environment necessary for implementation (see table 3). For example, developing a 
strategy to translate the success of Scandinavian countries in limiting antibiotic use in livestock rearing 
- while maintaining meat production and profits in LMICs (or other HICs) remains problematic. 
Without significant European Union subsidies, many livestock farmers in the region would be unable 
to operate profitably. The generalisability of demonstrably effective policies therefore remains a 




Stewardship programmes in both outpatient and hospital settings can effectively encourage 
responsible use of antibiotics and their implementation should be scaled up in both HICs and LMICs. 
The evidence base is stronger for interventions applied in secondary care settings, including the 
implementation of clinical guidelines and those targeting prescribing behaviour, but the potential total 
impact will be higher in community settings thereby indicating the need for more rigorous studies. In 
community settings back up/delayed prescribing has been shown to be effective, as are policies 
providing alternative appropriate prescribing options to antibiotics. Awareness-raising campaigns can 
also be effective when sustained, but should be implemented with caution particularly in LMICs, 
where the cost and impact of such campaigns needs better evaluation. In the animal sector, evidence 
from HICs suggests that curbing antibiotic use as growth promoters can reduce AMR. However, bans 
or other policy measures to achieve this must be coupled with adequate investment in improved IPCI 
for livestock, and effective mechanisms for remunerating veterinarians/veterinary officers and re-
orienting their roles. 
Arguably, the greatest potential impact globally on reducing the demand and need for antimicrobials 
comes from IPCIs, including vaccinations, hand washing, and improved access to water and 
sanitation. Where possible, collaborations should continue, with a focus on promoting IPCI in LMICs, 
which often lag behind in this area.198 AMR strategies must thus look for opportunities to integrate 
their activities and goals into these closely related development sectors. 
 A move to increase implementation of effective responsible use interventions and IPCIs globally 
could be linked to a simultaneous push for improved resistance surveillance and antimicrobial use 
monitoring data, thereby securing accountability. Countries reporting emerging drug resistance 
levels or high antimicrobial usage should be offered financial and technical support for implementing 
interventions to help reverse such trends, but should also be incentivized to invest systematically 
domestically.   
With a host of surveillance systems operating in parallel worldwide, countries and regions need to 
adopt those which best suit their needs and a broad cross-sectoral and multi-stakeholder programme 
of harmonisation and integration of global systems should be fostered for more meaningful between-
country comparisons of AMR and antibiotic use. This would allow for a sustainable and ordered 
integration of regions into a globalised surveillance system. For LMICs, improving monitoring of drug 
quality to curb the proliferation of counterfeits and substandard antimicrobials is also necessary. IPCI 
and surveillance in the animal and environmental sectors suffer from chronic underfunding and 
political appetite for investment is required to spend the several billion dollars per annum necessary 
to upgrade capacity in many LMICs.  
Need for better evaluations 
To address evidence gaps, comprehensive evaluations are needed and systematic reviews of 
interventions used in existing policies as related to AMR control are required.  Support for  
evaluating policies is especially necessary in LMICs and, specifically, in the animal and environmental 
sectors. Standardised frameworks for policy evaluations should be developed and applied for each 
sector. Even where such frameworks exist (such as for surveillance) they are seldom applied fully or 
as recommended even in well-resourced settings like Europe.26 Given the complexity of designing 
appropriate evaluation frameworks and the well-described risks of misleading conclusions around 
generalisibility if the wrong framework is applied, a technical expert-led taskforce should be 
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convened with representation from all sectors for this purpose.199,200  Particular care would need to 
be paid to including standardised analyses of contextual factors like political structures, governance 
and regulation, and resource availability (human/financial and infrastructural) to obtain meaningful 
evaluations. Detailed case study approaches may therefore be most suitable, and an open-access 
central repository should be established where AMR policy case studies could be captured to 
facilitate lesson-learning and best practice comparisons.200 This could be operated in a manner 
similar to PreventionWeb – the United Nations’ website capturing case studies on different aspects 
of Disaster Risk Reduction.201  
Conclusion 
Even though the evidence base for policy interventions to combat AMR is scattered, there is still a 
rich menu of options for countries to choose from. However, these options need to be adapted 
before adoption to adjust for the specific context. This then calls for proper surveillance and 
monitoring to be able to track and evaluate progress and contribute to an expanding knowledge 
base across countries.   
The analysis presented here focused on the human and animal sectors with limited  discussion of 
environment-related AMR control and of food and trade policy. However, these too are integral 
components of AMR control and the ‘One Health’ approach to policy development advocated here 
may help to bridge gaps in the levels of commitment being shown to each sector. Powerful vested 
interests are able to derail a coordinated strategy both intentionally and unintentionally. These 
range from industry battles between competing lobby groups over antibiotic use in animals, to the 
continuing tussles of donor-funded vertical healthcare programmes in LMICs that could potentially 
compete with AMR control programmes for limited resources. Consequently, in all regions, a sound 
understanding of the political and economic context is as important as the scientific evidence base in 
developing coordinated and effective policies to control AMR. The wide ranging sensitivities at play 
mean it is important that a unified, inclusive process to policy development is adopted; one that is 
sufficiently flexible to accommodate the varying needs and circumstances of countries and regions, 
and one that is fully funded and implemented.  
Table 3: A summary of potentially effective AMR control interventions and challenges in developing 
generalisable policies   
 
 Examples of effective 
interventions/policies 
Weakness in evidence base Challenges for generalisability of policy 
Responsible Use  Providing alternative 
prescribing options at a 
national level for 
antibiotics (e.g. zinc and 
oral rehydration for 
diarrhoeal illness) 
 Back-up/Delayed 
prescribing in publically 
 Long-terms impacts on 
prescribing behaviour have not 
been assessed 
 A dearth of robust cost-
effectiveness analyses of all 
interventions 
 Very little research done on 
interventions targeted at the 
 Widely varying governance 
structures and accountability 
mechanisms of health systems 
 Different methods of 
prescriber remuneration 
 Behaviour change 







funded high income 
settings.. 
 Development and 
implementation of clinical  
antibiotic guidelines in 
secondary care 
 Persuasive/Restrictive 
interventions in secondary 
care 
 National restrictions on 
antibiotic subsidies 
 Providing alternative re-
imbursement options for 
prescribers ( in both 
human and animal 
settings) 
 Bans on antibiotic use as 
AGPs 
 Re-orienting prescriber 
roles in the animal sector 
(unregulated) private sector in 
LMICs 
 The impact of regulatory policies 
on marketing and sale of 




cultural  settings where  they 
have bee n trialled 
 Financial challenges in the 
animal/livestock sector such as 
capital costs for changing 
practice, meat prices and farm 
profitability. 
 Wide national variations in 
health budget availability for 
AMR policies 
 The unregulated proliferation 






 Hand hygiene promotion 
interventions in healthcare 
and community settings 
 Improving access to water 
and sanitation  
 Increasing effective vaccine 
coverage in both human 
and animal sectors 
 
 Evidence on effectiveness and 
appropriate implementation on 
IPCIs in LMICs is lacking. 
 Poor cost-effectiveness 




 A lack of integration of IPCI 
programmes in the community 
and AMR control policy.  
 Chronic underfunding of IPCI in 
the animal/livestock sector 
Surveillance  Integrate AMR surveillance 
and antimicrobial use on a 
regional basis to enable 
between-country 
comparisons. 
 Link surveillance  of AMR in 
the animal  sector to 
regulatory sanctions 
against bad practice 
 The evidence base to determine 
the most cost-effective systems 
for surveillance of antibiotic use 
and resistance remain weak 
worldwide 
 A lack of analysis of 
infrastructure and resource 
requirements for effective 
surveillance  
 Significant differences across 
countriesof surveillance system 
indicators and guidelines for 
surveillance of antibiotic use and 
resistance in different settings; 
comparative data in human and 
animal health is therefore 
lacking 
 
 Transferability of surveillance 
systems that have been 
successful in HICs to LMICs is 
questionable due to 
infrastructure and resource 
differences 
 Surveillance of 
counterfeit/substandard 
antimicrobials also a priority in 
LMICs 
 Chronic underfunding of 
surveillance in the animal 
sector in LMICs 
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